Wednesday 17 June, 2026
Welcome to the home of pharma innovation
Building on the success of the Pharma and Life Sciences Summit at HLTH Europe 2025, the exclusive one day Summit is where bold ideas meet real-world impact.
Designed to address pharma’s biggest commercial and strategic challenges, the Summit explores how innovation, new technologies, partnerships, and new business models can drive impact at scale.
Join 250 industry leaders to gain insights, forge collaborations, and accelerate growth in a rapidly evolving healthcare landscape.
Pharma attendees include:
Who's coming?
We’re convening the key players of life sciences - C-suite leaders from pharma and biotech, top regulators, and senior innovators - for an exclusive, behind-closed-doors gathering.
Pharma and biotech leaders
The core of the Summit: Senior executives from the world’s top pharma companies alongside leading biotech innovators.
Policy and regulatory stakeholders
Influential policymakers and regulators who help shape the environment in which pharma operates.
Innovators and partners
Handpicked senior leaders from technology, investment, and strategic healthcare organisations who bring fresh perspectives and opportunities for collaboration.
Pharma Summit snapshot
"HLTH Europe is the ONE event everyone in healthcare should attend."
Lu Zheng
VP, Head of Digital Health
Takeda Pharmaceuticals
An exclusive, curated programme
The Global Pharma Summit at HLTH Europe convenes an exclusive group of the world’s leading pharma executives, policymakers, and stakeholders to connect, exchange insights, and shape the future of the industry.
Through a thoughtfully curated programme of strategic discussions, case studies, interactive roundtables, and high-impact networking, the Summit fosters candid dialogue and collaboration across the global pharma community in a distinctive and intimate setting.
The Summit runs all day on Wednesday, 17 June 2026.
All attendees require a ticket to HLTH Europe and can join HLTH Europe programming from Monday to Thursday.
Themes include the future of R&D and clinical development, regulatory science and policy, commercial innovation, digital transformation, and access to medicines worldwide.
